Form 4: Silo Pharma CEO Eric Weisblum Acquires Additional Shares

Silo Pharma's CEO, Eric Weisblum, recently purchased additional shares of the company's common stock in two separate transactions.

Summary

• On March 28, 2024, Eric Weisblum, the CEO and President of Silo Pharma, Inc., acquired 3,408 shares of common stock at a weighted average price of $1.94.
• These shares were purchased in multiple transactions with prices ranging from $1.91 to $1.95.
• Following this transaction, Weisblum directly owned 173,332 shares.
• On April 1, 2024, Weisblum acquired an additional 1,100 shares of common stock at a weighted average price of $1.91.
• These shares were purchased in multiple transactions with prices ranging from $1.90 to $1.93.
• Following this transaction, Weisblum directly owned 174,432 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CEO's stock purchase is a positive sign, but the document itself is simply a regulatory filing.

Positives

• The CEO's purchase of additional shares could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Insider buying is often seen as a positive signal, suggesting that a company's leadership believes the stock is undervalued.

Stakeholder Impact

• The CEO's stock purchase could positively influence shareholder sentiment.

Key Dates

Keywords

Silo Pharma, Eric Weisblum, stock acquisition, common stock, insider trading, SEC Form 4